Consider discussing a protocol review with your provider
doi: 10.1002/biof.5520080102
However, there was a statistically significant reduction in the risk of hypoglycemia by about 30% [RR=0.70, 95% CI (0.57, 0.87), p =0.001] ( Figure 4 ), and pneumonia by about 25% [RR=0.85, 95% CI (0.75, 0.97), p =0.01] ( Figure 5 )
[DOI] [PMC free article] [PubMed] [Google Scholar] 118.Craft N.E., Haitema T.B., Garnett K.M., Fitch K.A., Dorey C.K
What we should not do is take a wait-and-see position, hoping that research groups will come along to propose and scrape together funding for long-term trials that may not give us actionable results before 2030